Middle East Healthcare Co CJSC (4009) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Middle East Healthcare Co CJSC stock SAR 58.54, price SAR 24.08, upside +143.1%, quality 42 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
Cheap, value-trap riskFair value well above the price, but weak quality and a downtrend.Plus: Even on cautious assumptions the value is 70% above the price (40.98 SAR).
The stock costs 59% less than our calculation considers fair.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range 22.29 SAR – 128.21 SAR · fair‑value band 40.98 SAR – 76.11 SAR · the 24.08 SAR price screens below the 58.54 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow Middle East Healthcare Co CJSC in your weekly email
Every Wednesday you see whether Middle East Healthcare Co CJSC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Middle East Healthcare Company, a healthcare provider, owns and operates a network of hospitals under the Saudi German Hospital name in the Kingdom of Saudi Arabia and internationally.
Show moreShow less
The company operates, manages, and maintains hospitals; and medical, educational, rehabilitation, laboratories and radiology, physiotherapy, and pharmacies centers. It also buys land to construct medical projects, as well as to establish, manage, construct, and organize exhibitions.
The company was founded in 1988 and is based in Jeddah, the Kingdom of Saudi Arabia. Middle East Healthcare Company operates as a subsidiary of Bait Al Batterjee Medical Co. Ltd.
Stock analysis
Middle East Healthcare Co CJSC (4009) currently trades at 24.08 SAR, while our model-based Fair Value estimate is 58.54 SAR, implying the stock looks roughly 58.9% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 58.54 SAR per share, and 10 of the 16 models we run sit above the 24.08 SAR price.
Bear case: the Dividend Discount group reads lowest at 5.92 SAR, and 6 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 40.98 SAR (bear) to 76.11 SAR (bull), the price of 24.08 SAR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Middle East Healthcare Co CJSC reported revenue of 3.1B SAR in FY2025 versus 1.9B SAR in FY2021, a compound +13.5%/yr. Reported net income was 302M SAR in FY2025, compounding +125.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 2.2B SAR (≈ $591M) Small · P/E ratio 15.1 · P/S ratio 0.70 · EPS (TTM) 1.59 SAR · Dividend yield 2.1% · Net margin 4.3% · Return on equity 9.1% · Return on assets (EBIT) 5.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 143%, 4009 screens cheaper than that median.
Fair Value models
Bear40.98 SARFair Value 58.54 SARBull76.11 SAR
Price 24.08 SAR · Upside +143.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.9019 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Start year 2020 (pandemic). Over 10 years: +7.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +32.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +30.5%
Dividend (yield on the price)2.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 29.8% / −1.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 13%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 1.12 per share, median 3.51 in 2015 to 2018). It measures the recovery from the trough, not lasting growth.
⚠ Rate on operating basis: 2025 sits 68% above its own trend.
Compare Middle East Healthcare Co CJSC with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 243 stocks
Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score42 · Bottom 25%
Fair Value upside+143.1% · Top 25%
Profitability
Return on equity (12 months)9.1% · Above median
Return on assets5.5% · Above median
Net margin (12 months)4.3% · Below median
Operating margin (12 months)10.8% · Above median
Growth and dividend
Revenue growth (quarter YoY)6.9% · Above median
Dividend yield (12 months)2.1% · Above median
Balance sheet
Debt / equity0.85× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Middle East Healthcare Co CJSC Fair Value". https://www.fairvalue-calculator.com/stock/4009
Frequently asked questions
Is Middle East Healthcare Co CJSC (4009) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of 58.54 SAR versus a price of 24.08 SAR, about +143% upside (undervalued).
What is the fair value of 4009?
Our model-based fair value for Middle East Healthcare Co CJSC is 58.54 SAR (as of Oct 27, 2026), built from audited fundamentals. The current price: 24.08 SAR.
What is the quality score of 4009?
Middle East Healthcare Co CJSC has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Middle East Healthcare Co CJSC (4009)?
Our model-based price target is the fair value of 58.54 SAR (as of Oct 27, 2026) from 16 valuation models. Cautious scenario 40.98 SAR, optimistic scenario 76.11 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Middle East Healthcare Co CJSC stock forecast for 2026?
Our models put fair value at 58.54 SAR, about +143% upside versus a price of 24.08 SAR (undervalued). Cautious scenario 40.98 SAR, optimistic scenario 76.11 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Middle East Healthcare Co CJSC (4009)?
Middle East Healthcare Co CJSC reported trailing-twelve-month revenue of about 3.2B SAR (latest available figure, as of Oct 27, 2026).
Does Middle East Healthcare Co CJSC pay a dividend?
Middle East Healthcare Co CJSC currently shows a dividend yield of 2.08% relative to its recent price (as of Oct 27, 2026).
What is the intrinsic value of Middle East Healthcare Co CJSC (4009)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Middle East Healthcare Co CJSC it is 58.54 SAR per share (as of Oct 27, 2026), against a price of 24.08 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Middle East Healthcare Co CJSC stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 4009 trades below its calculated fair value: price 24.08 SAR, fair value 58.54 SAR, a gap of about +143% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4009?
No. The price is what the market pays today (24.08 SAR); the fair value is what the company's own numbers justify (58.54 SAR). For Middle East Healthcare Co CJSC the two are 34.46 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Middle East Healthcare Co CJSC worth?
The market values Middle East Healthcare Co CJSC at about 2.2B SAR (market capitalisation, as of Oct 27, 2026). Per share that is 24.08 SAR; our models calculate a fair value of 58.54 SAR per share.
What do the bullish and bearish scenarios say about 4009?
Our models span a range for Middle East Healthcare Co CJSC: cautious scenario 40.98 SAR, base 58.54 SAR, optimistic 76.11 SAR per share (as of Oct 27, 2026, price 24.08 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4009?
Middle East Healthcare Co CJSC trades at a price-to-earnings ratio of 15.1 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 58.54 SAR is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 7.3 (reported for FY2025: 5.8). Other multiples: P/B 1.2, P/S 0.7, EV/EBITDA 7.4.
How solid is the balance sheet of Middle East Healthcare Co CJSC (4009)?
Balance-sheet figures for Middle East Healthcare Co CJSC (as of Oct 27, 2026): return on equity 9.1%, debt of 0.85 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 4009 from its 52-week high?
Middle East Healthcare Co CJSC trades at 24.08 SAR, about 53% below its 52-week high of 50.79 SAR and 8% above the low of 22.29 SAR (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 58.54 SAR is for.
Which stocks are comparable to Middle East Healthcare Co CJSC?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Middle East Healthcare Co CJSC stock attractive at the current price?
The data as of Oct 27, 2026: price 24.08 SAR, calculated fair value 58.54 SAR (+143%), Quality Score 42/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4009 calculated?
We run Middle East Healthcare Co CJSC through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 58.54 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Middle East Healthcare Co CJSC currently trades 59 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Middle East Healthcare Co CJSC (4009)?
The closing price on Oct 28, 2026 was 24.08 SAR. Our model-based fair value is 58.54 SAR, about +143% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Middle East Healthcare Co CJSC right now?
The large discount to fair value meets weak quality (42/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (40.98 SAR). The market is more pessimistic than our downside scenario. A fairly wide model range (40.98 SAR to 76.11 SAR) leaves room in how you read the outcome.
Where does the earnings growth of Middle East Healthcare Co CJSC (4009) come from?
Earnings per share at Middle East Healthcare Co CJSC grew −3.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.4 %, EBIT margin −6.0 %, tax rate −0.8 %, residual (interest, one-offs) −3.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Middle East Healthcare Co CJSC
How large is the market capitalisation of Middle East Healthcare Co CJSC (4009)?
The market capitalisation of Middle East Healthcare Co CJSC is 2.2B SAR (≈ $591M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Middle East Healthcare Co CJSC (4009)?
The price-to-sales ratio of Middle East Healthcare Co CJSC is 0.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Middle East Healthcare Co CJSC (4009)?
Earnings per share at Middle East Healthcare Co CJSC are 1.59 SAR (price ÷ EPS = P/E 15.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Middle East Healthcare Co CJSC (4009)?
The dividend yield of Middle East Healthcare Co CJSC is 2.1% (payout 40.0%, on adjusted earnings, reported 31.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Middle East Healthcare Co CJSC (4009)?
The net margin of Middle East Healthcare Co CJSC is 4.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Middle East Healthcare Co CJSC (4009)?
The return on equity (ROE) of Middle East Healthcare Co CJSC is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Middle East Healthcare Co CJSC (4009)?
On an EBIT basis the return on assets of Middle East Healthcare Co CJSC is 5.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Middle East Healthcare Co CJSC (4009)?
The operating margin of Middle East Healthcare Co CJSC is 10.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Middle East Healthcare Co CJSC (4009)?
Revenue at Middle East Healthcare Co CJSC is growing +6.9% versus a year earlier (3y avg +13.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Middle East Healthcare Co CJSC (4009)?
Earnings per share at Middle East Healthcare Co CJSC are growing +68.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Middle East Healthcare Co CJSC (4009) generate?
The free cash flow of Middle East Healthcare Co CJSC is −99.8M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Middle East Healthcare Co CJSC (4009) carry?
The net debt of Middle East Healthcare Co CJSC is 2.5B SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Middle East Healthcare Co CJSC in the live analysis
One click puts Middle East Healthcare Co CJSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 27, 2026